Filing Details

Accession Number:
0001209191-23-037029
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-14 16:28:46
Reporting Period:
2023-06-12
Accepted Time:
2023-06-14 16:28:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1563880 Trevi Therapeutics Inc. TRVI Pharmaceutical Preparations (2834) 450834299
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1873253 Lisa Delfini C/O Trevi Therapeutics, Inc.
195 Church Street, 16Th Floor
New Haven CT 06510
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-12 2,291 $0.51 30,209 No 4 M Direct
Common Stock Disposition 2023-06-12 610 $2.64 29,599 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-06-12 2,291 $0.00 2,291 $0.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,335 2032-02-10 No 4 M Direct
Footnotes
  1. This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022.
  2. This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on June 12, 2023.
  3. This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.